nodes	percent_of_prediction	percent_of_DWPC	metapath
Rilpivirine—NR1I2—bone cancer	0.543	0.835	CbGaD
Rilpivirine—CYP3A4—bone cancer	0.107	0.165	CbGaD
Rilpivirine—SLCO1B3—Methotrexate—bone cancer	0.054	0.178	CbGbCtD
Rilpivirine—ABCG2—Carboplatin—bone cancer	0.045	0.149	CbGbCtD
Rilpivirine—ABCG2—Cisplatin—bone cancer	0.0385	0.127	CbGbCtD
Rilpivirine—SLCO1B1—Methotrexate—bone cancer	0.0314	0.104	CbGbCtD
Rilpivirine—CYP2B6—Cisplatin—bone cancer	0.0271	0.0894	CbGbCtD
Rilpivirine—ABCG2—Doxorubicin—bone cancer	0.0258	0.0852	CbGbCtD
Rilpivirine—ABCG2—Methotrexate—bone cancer	0.025	0.0825	CbGbCtD
Rilpivirine—CYP2B6—Doxorubicin—bone cancer	0.0181	0.0599	CbGbCtD
Rilpivirine—ABCB1—Cisplatin—bone cancer	0.0139	0.0458	CbGbCtD
Rilpivirine—ABCB1—Doxorubicin—bone cancer	0.00929	0.0307	CbGbCtD
Rilpivirine—ABCB1—Methotrexate—bone cancer	0.009	0.0298	CbGbCtD
Rilpivirine—CYP3A4—Doxorubicin—bone cancer	0.00557	0.0184	CbGbCtD
Rilpivirine—Pazopanib—KIT—bone cancer	0.00227	0.523	CrCbGaD
Rilpivirine—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.0015	0.059	CbGpPWpGaD
Rilpivirine—NR1I2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00149	0.0585	CbGpPWpGaD
Rilpivirine—Etravirine—CYP3A4—bone cancer	0.00144	0.332	CrCbGaD
Rilpivirine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00124	0.0486	CbGpPWpGaD
Rilpivirine—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00102	0.0401	CbGpPWpGaD
Rilpivirine—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000957	0.0376	CbGpPWpGaD
Rilpivirine—Bilirubin total increased—Epirubicin—bone cancer	0.000938	0.0536	CcSEcCtD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000884	0.0347	CbGpPWpGaD
Rilpivirine—Bilirubin total increased—Doxorubicin—bone cancer	0.000868	0.0496	CcSEcCtD
Rilpivirine—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000856	0.0336	CbGpPWpGaD
Rilpivirine—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00069	0.0271	CbGpPWpGaD
Rilpivirine—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.000653	0.0256	CbGpPWpGaD
Rilpivirine—Pazopanib—CYP3A4—bone cancer	0.000627	0.145	CrCbGaD
Rilpivirine—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000605	0.0237	CbGpPWpGaD
Rilpivirine—Serum creatinine increased—Cisplatin—bone cancer	0.000596	0.034	CcSEcCtD
Rilpivirine—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00058	0.0228	CbGpPWpGaD
Rilpivirine—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000559	0.022	CbGpPWpGaD
Rilpivirine—NR1I2—Generic Transcription Pathway—ZNF77—bone cancer	0.000541	0.0212	CbGpPWpGaD
Rilpivirine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000522	0.0205	CbGpPWpGaD
Rilpivirine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000511	0.0201	CbGpPWpGaD
Rilpivirine—Opportunistic infection—Methotrexate—bone cancer	0.000499	0.0285	CcSEcCtD
Rilpivirine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000479	0.0188	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000478	0.0188	CbGpPWpGaD
Rilpivirine—Hepatotoxicity—Cisplatin—bone cancer	0.000475	0.0271	CcSEcCtD
Rilpivirine—Opportunistic infection—Epirubicin—bone cancer	0.000467	0.0267	CcSEcCtD
Rilpivirine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000454	0.0178	CbGpPWpGaD
Rilpivirine—Infection—Carboplatin—bone cancer	0.000443	0.0253	CcSEcCtD
Rilpivirine—Opportunistic infection—Doxorubicin—bone cancer	0.000432	0.0247	CcSEcCtD
Rilpivirine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000407	0.016	CbGpPWpGaD
Rilpivirine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000373	0.0146	CbGpPWpGaD
Rilpivirine—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000359	0.0141	CbGpPWpGaD
Rilpivirine—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000333	0.0131	CbGpPWpGaD
Rilpivirine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000314	0.0123	CbGpPWpGaD
Rilpivirine—Transaminases increased—Epirubicin—bone cancer	0.000309	0.0177	CcSEcCtD
Rilpivirine—Serum creatinine increased—Epirubicin—bone cancer	0.000306	0.0175	CcSEcCtD
Rilpivirine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000297	0.0117	CbGpPWpGaD
Rilpivirine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000295	0.0116	CbGpPWpGaD
Rilpivirine—Transaminases increased—Doxorubicin—bone cancer	0.000286	0.0164	CcSEcCtD
Rilpivirine—Serum creatinine increased—Doxorubicin—bone cancer	0.000283	0.0162	CcSEcCtD
Rilpivirine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00028	0.011	CbGpPWpGaD
Rilpivirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000275	0.0108	CbGpPWpGaD
Rilpivirine—Hepatotoxicity—Methotrexate—bone cancer	0.000261	0.0149	CcSEcCtD
Rilpivirine—NR1I2—Gene Expression—ZNF77—bone cancer	0.00026	0.0102	CbGpPWpGaD
Rilpivirine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000252	0.00989	CbGpPWpGaD
Rilpivirine—Blood creatinine increased—Cisplatin—bone cancer	0.000249	0.0142	CcSEcCtD
Rilpivirine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000242	0.00951	CbGpPWpGaD
Rilpivirine—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00024	0.0137	CcSEcCtD
Rilpivirine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000235	0.00921	CbGpPWpGaD
Rilpivirine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000229	0.00898	CbGpPWpGaD
Rilpivirine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000225	0.00882	CbGpPWpGaD
Rilpivirine—Abdominal discomfort—Cisplatin—bone cancer	0.000221	0.0126	CcSEcCtD
Rilpivirine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00022	0.00862	CbGpPWpGaD
Rilpivirine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000218	0.00856	CbGpPWpGaD
Rilpivirine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000213	0.00838	CbGpPWpGaD
Rilpivirine—Inflammation—Methotrexate—bone cancer	0.000207	0.0118	CcSEcCtD
Rilpivirine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000204	0.00803	CbGpPWpGaD
Rilpivirine—Renal failure—Cisplatin—bone cancer	0.000202	0.0115	CcSEcCtD
Rilpivirine—Blood bilirubin increased—Epirubicin—bone cancer	0.000199	0.0114	CcSEcCtD
Rilpivirine—Creatinine increased—Epirubicin—bone cancer	0.000198	0.0113	CcSEcCtD
Rilpivirine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000196	0.0077	CbGpPWpGaD
Rilpivirine—Inflammation—Epirubicin—bone cancer	0.000194	0.0111	CcSEcCtD
Rilpivirine—Hepatobiliary disease—Cisplatin—bone cancer	0.000194	0.0111	CcSEcCtD
Rilpivirine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000189	0.00741	CbGpPWpGaD
Rilpivirine—Abnormal dreams—Epirubicin—bone cancer	0.000186	0.0106	CcSEcCtD
Rilpivirine—Blood bilirubin increased—Doxorubicin—bone cancer	0.000184	0.0105	CcSEcCtD
Rilpivirine—Creatinine increased—Doxorubicin—bone cancer	0.000183	0.0105	CcSEcCtD
Rilpivirine—Urinary tract disorder—Cisplatin—bone cancer	0.000182	0.0104	CcSEcCtD
Rilpivirine—Urethral disorder—Cisplatin—bone cancer	0.00018	0.0103	CcSEcCtD
Rilpivirine—Inflammation—Doxorubicin—bone cancer	0.00018	0.0103	CcSEcCtD
Rilpivirine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000175	0.00687	CbGpPWpGaD
Rilpivirine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000173	0.00679	CbGpPWpGaD
Rilpivirine—Abnormal dreams—Doxorubicin—bone cancer	0.000172	0.00983	CcSEcCtD
Rilpivirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00017	0.00666	CbGpPWpGaD
Rilpivirine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000169	0.00662	CbGpPWpGaD
Rilpivirine—Immune system disorder—Cisplatin—bone cancer	0.000166	0.0095	CcSEcCtD
Rilpivirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000161	0.00631	CbGpPWpGaD
Rilpivirine—Malnutrition—Cisplatin—bone cancer	0.00016	0.00915	CcSEcCtD
Rilpivirine—Renal impairment—Epirubicin—bone cancer	0.000144	0.0082	CcSEcCtD
Rilpivirine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000138	0.00543	CbGpPWpGaD
Rilpivirine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000137	0.00536	CbGpPWpGaD
Rilpivirine—Anxiety—Cisplatin—bone cancer	0.000136	0.00777	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000136	0.00774	CcSEcCtD
Rilpivirine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000135	0.0053	CbGpPWpGaD
Rilpivirine—Renal impairment—Doxorubicin—bone cancer	0.000133	0.00759	CcSEcCtD
Rilpivirine—Infection—Cisplatin—bone cancer	0.00013	0.00742	CcSEcCtD
Rilpivirine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.00013	0.00509	CbGpPWpGaD
Rilpivirine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000128	0.00504	CbGpPWpGaD
Rilpivirine—Nervous system disorder—Cisplatin—bone cancer	0.000128	0.00733	CcSEcCtD
Rilpivirine—Blood creatinine increased—Epirubicin—bone cancer	0.000128	0.00731	CcSEcCtD
Rilpivirine—NR1I2—Gene Expression—FUS—bone cancer	0.000127	0.00499	CbGpPWpGaD
Rilpivirine—Skin disorder—Cisplatin—bone cancer	0.000127	0.00726	CcSEcCtD
Rilpivirine—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000123	0.00703	CcSEcCtD
Rilpivirine—Abdominal discomfort—Methotrexate—bone cancer	0.000121	0.00691	CcSEcCtD
Rilpivirine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000121	0.00688	CcSEcCtD
Rilpivirine—Blood creatinine increased—Doxorubicin—bone cancer	0.000118	0.00677	CcSEcCtD
Rilpivirine—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000114	0.0065	CcSEcCtD
Rilpivirine—Decreased appetite—Cisplatin—bone cancer	0.000114	0.00649	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000113	0.00645	CcSEcCtD
Rilpivirine—Depression—Methotrexate—bone cancer	0.000112	0.00641	CcSEcCtD
Rilpivirine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000112	0.0044	CbGpPWpGaD
Rilpivirine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000112	0.00637	CcSEcCtD
Rilpivirine—Renal failure—Methotrexate—bone cancer	0.000111	0.00632	CcSEcCtD
Rilpivirine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000111	0.00434	CbGpPWpGaD
Rilpivirine—Hepatobiliary disease—Methotrexate—bone cancer	0.000106	0.00608	CcSEcCtD
Rilpivirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000105	0.0041	CbGpPWpGaD
Rilpivirine—Renal failure—Epirubicin—bone cancer	0.000104	0.00591	CcSEcCtD
Rilpivirine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000103	0.00405	CbGpPWpGaD
Rilpivirine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000101	0.00396	CbGpPWpGaD
Rilpivirine—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.0001	0.00393	CbGpPWpGaD
Rilpivirine—Urinary tract disorder—Methotrexate—bone cancer	9.98e-05	0.0057	CcSEcCtD
Rilpivirine—Hepatobiliary disease—Epirubicin—bone cancer	9.96e-05	0.00569	CcSEcCtD
Rilpivirine—Urethral disorder—Methotrexate—bone cancer	9.9e-05	0.00566	CcSEcCtD
Rilpivirine—Renal failure—Doxorubicin—bone cancer	9.58e-05	0.00547	CcSEcCtD
Rilpivirine—Asthenia—Cisplatin—bone cancer	9.38e-05	0.00536	CcSEcCtD
Rilpivirine—Urinary tract disorder—Epirubicin—bone cancer	9.34e-05	0.00533	CcSEcCtD
Rilpivirine—Urethral disorder—Epirubicin—bone cancer	9.27e-05	0.00529	CcSEcCtD
Rilpivirine—Hepatobiliary disease—Doxorubicin—bone cancer	9.22e-05	0.00526	CcSEcCtD
Rilpivirine—Immune system disorder—Methotrexate—bone cancer	9.13e-05	0.00521	CcSEcCtD
Rilpivirine—Diarrhoea—Cisplatin—bone cancer	8.95e-05	0.00511	CcSEcCtD
Rilpivirine—Mental disorder—Methotrexate—bone cancer	8.85e-05	0.00506	CcSEcCtD
Rilpivirine—Malnutrition—Methotrexate—bone cancer	8.79e-05	0.00502	CcSEcCtD
Rilpivirine—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.65e-05	0.00339	CbGpPWpGaD
Rilpivirine—Urinary tract disorder—Doxorubicin—bone cancer	8.64e-05	0.00493	CcSEcCtD
Rilpivirine—Urethral disorder—Doxorubicin—bone cancer	8.58e-05	0.0049	CcSEcCtD
Rilpivirine—Immune system disorder—Epirubicin—bone cancer	8.54e-05	0.00488	CcSEcCtD
Rilpivirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.48e-05	0.00333	CbGpPWpGaD
Rilpivirine—Vomiting—Cisplatin—bone cancer	8.32e-05	0.00475	CcSEcCtD
Rilpivirine—Mental disorder—Epirubicin—bone cancer	8.28e-05	0.00473	CcSEcCtD
Rilpivirine—Rash—Cisplatin—bone cancer	8.25e-05	0.00471	CcSEcCtD
Rilpivirine—Dermatitis—Cisplatin—bone cancer	8.24e-05	0.00471	CcSEcCtD
Rilpivirine—Malnutrition—Epirubicin—bone cancer	8.23e-05	0.0047	CcSEcCtD
Rilpivirine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	8.15e-05	0.0032	CbGpPWpGaD
Rilpivirine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	8.04e-05	0.00316	CbGpPWpGaD
Rilpivirine—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	8.03e-05	0.00315	CbGpPWpGaD
Rilpivirine—Immune system disorder—Doxorubicin—bone cancer	7.9e-05	0.00451	CcSEcCtD
Rilpivirine—SLCO1B3—Metabolism—NDUFA12—bone cancer	7.83e-05	0.00307	CbGpPWpGaD
Rilpivirine—Nausea—Cisplatin—bone cancer	7.77e-05	0.00444	CcSEcCtD
Rilpivirine—Mental disorder—Doxorubicin—bone cancer	7.66e-05	0.00438	CcSEcCtD
Rilpivirine—Malnutrition—Doxorubicin—bone cancer	7.62e-05	0.00435	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.44e-05	0.00425	CcSEcCtD
Rilpivirine—Infection—Methotrexate—bone cancer	7.13e-05	0.00407	CcSEcCtD
Rilpivirine—Nervous system disorder—Methotrexate—bone cancer	7.04e-05	0.00402	CcSEcCtD
Rilpivirine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	7e-05	0.00275	CbGpPWpGaD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	6.99e-05	0.00274	CbGpPWpGaD
Rilpivirine—Anxiety—Epirubicin—bone cancer	6.98e-05	0.00399	CcSEcCtD
Rilpivirine—Skin disorder—Methotrexate—bone cancer	6.97e-05	0.00398	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.96e-05	0.00397	CcSEcCtD
Rilpivirine—Dry mouth—Epirubicin—bone cancer	6.85e-05	0.00391	CcSEcCtD
Rilpivirine—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.73e-05	0.00264	CbGpPWpGaD
Rilpivirine—Infection—Epirubicin—bone cancer	6.67e-05	0.00381	CcSEcCtD
Rilpivirine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.6e-05	0.00259	CbGpPWpGaD
Rilpivirine—Nervous system disorder—Epirubicin—bone cancer	6.59e-05	0.00376	CcSEcCtD
Rilpivirine—Skin disorder—Epirubicin—bone cancer	6.52e-05	0.00373	CcSEcCtD
Rilpivirine—NR1I2—Gene Expression—EIF2S1—bone cancer	6.51e-05	0.00256	CbGpPWpGaD
Rilpivirine—Insomnia—Methotrexate—bone cancer	6.49e-05	0.00371	CcSEcCtD
Rilpivirine—SLCO1B3—Metabolism—NT5C3A—bone cancer	6.49e-05	0.00255	CbGpPWpGaD
Rilpivirine—Anxiety—Doxorubicin—bone cancer	6.46e-05	0.00369	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.44e-05	0.00368	CcSEcCtD
Rilpivirine—Somnolence—Methotrexate—bone cancer	6.38e-05	0.00364	CcSEcCtD
Rilpivirine—Dry mouth—Doxorubicin—bone cancer	6.34e-05	0.00362	CcSEcCtD
Rilpivirine—Decreased appetite—Methotrexate—bone cancer	6.24e-05	0.00356	CcSEcCtD
Rilpivirine—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.23e-05	0.00245	CbGpPWpGaD
Rilpivirine—Gastrointestinal disorder—Methotrexate—bone cancer	6.2e-05	0.00354	CcSEcCtD
Rilpivirine—Fatigue—Methotrexate—bone cancer	6.19e-05	0.00353	CcSEcCtD
Rilpivirine—Infection—Doxorubicin—bone cancer	6.17e-05	0.00353	CcSEcCtD
Rilpivirine—Nervous system disorder—Doxorubicin—bone cancer	6.09e-05	0.00348	CcSEcCtD
Rilpivirine—Insomnia—Epirubicin—bone cancer	6.08e-05	0.00347	CcSEcCtD
Rilpivirine—Skin disorder—Doxorubicin—bone cancer	6.04e-05	0.00345	CcSEcCtD
Rilpivirine—Somnolence—Epirubicin—bone cancer	5.97e-05	0.00341	CcSEcCtD
Rilpivirine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	5.96e-05	0.00234	CbGpPWpGaD
Rilpivirine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	5.88e-05	0.00231	CbGpPWpGaD
Rilpivirine—Gastrointestinal pain—Methotrexate—bone cancer	5.87e-05	0.00335	CcSEcCtD
Rilpivirine—Decreased appetite—Epirubicin—bone cancer	5.84e-05	0.00333	CcSEcCtD
Rilpivirine—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.81e-05	0.00228	CbGpPWpGaD
Rilpivirine—Gastrointestinal disorder—Epirubicin—bone cancer	5.8e-05	0.00331	CcSEcCtD
Rilpivirine—Fatigue—Epirubicin—bone cancer	5.79e-05	0.00331	CcSEcCtD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	5.73e-05	0.00225	CbGpPWpGaD
Rilpivirine—Abdominal pain—Methotrexate—bone cancer	5.67e-05	0.00324	CcSEcCtD
Rilpivirine—NR1I2—Gene Expression—EZH2—bone cancer	5.65e-05	0.00222	CbGpPWpGaD
Rilpivirine—Insomnia—Doxorubicin—bone cancer	5.62e-05	0.00321	CcSEcCtD
Rilpivirine—Somnolence—Doxorubicin—bone cancer	5.53e-05	0.00316	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Epirubicin—bone cancer	5.49e-05	0.00314	CcSEcCtD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	5.43e-05	0.00213	CbGpPWpGaD
Rilpivirine—Decreased appetite—Doxorubicin—bone cancer	5.4e-05	0.00309	CcSEcCtD
Rilpivirine—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.38e-05	0.00211	CbGpPWpGaD
Rilpivirine—Gastrointestinal disorder—Doxorubicin—bone cancer	5.37e-05	0.00306	CcSEcCtD
Rilpivirine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	5.36e-05	0.0021	CbGpPWpGaD
Rilpivirine—Fatigue—Doxorubicin—bone cancer	5.36e-05	0.00306	CcSEcCtD
Rilpivirine—Abdominal pain—Epirubicin—bone cancer	5.31e-05	0.00303	CcSEcCtD
Rilpivirine—SLCO1B1—Metabolism—NDUFA12—bone cancer	5.26e-05	0.00207	CbGpPWpGaD
Rilpivirine—Asthenia—Methotrexate—bone cancer	5.15e-05	0.00294	CcSEcCtD
Rilpivirine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	5.13e-05	0.00201	CbGpPWpGaD
Rilpivirine—CYP2B6—Biological oxidations—GSTP1—bone cancer	5.1e-05	0.002	CbGpPWpGaD
Rilpivirine—Gastrointestinal pain—Doxorubicin—bone cancer	5.08e-05	0.0029	CcSEcCtD
Rilpivirine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	5.03e-05	0.00197	CbGpPWpGaD
Rilpivirine—Abdominal pain—Doxorubicin—bone cancer	4.91e-05	0.00281	CcSEcCtD
Rilpivirine—Diarrhoea—Methotrexate—bone cancer	4.91e-05	0.0028	CcSEcCtD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	4.87e-05	0.00191	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—NDUFA12—bone cancer	4.87e-05	0.00191	CbGpPWpGaD
Rilpivirine—Asthenia—Epirubicin—bone cancer	4.82e-05	0.00275	CcSEcCtD
Rilpivirine—Dizziness—Methotrexate—bone cancer	4.75e-05	0.00271	CcSEcCtD
Rilpivirine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	4.63e-05	0.00182	CbGpPWpGaD
Rilpivirine—Diarrhoea—Epirubicin—bone cancer	4.6e-05	0.00262	CcSEcCtD
Rilpivirine—Vomiting—Methotrexate—bone cancer	4.56e-05	0.00261	CcSEcCtD
Rilpivirine—Rash—Methotrexate—bone cancer	4.53e-05	0.00258	CcSEcCtD
Rilpivirine—Dermatitis—Methotrexate—bone cancer	4.52e-05	0.00258	CcSEcCtD
Rilpivirine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	4.5e-05	0.00177	CbGpPWpGaD
Rilpivirine—Headache—Methotrexate—bone cancer	4.5e-05	0.00257	CcSEcCtD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	4.46e-05	0.00175	CbGpPWpGaD
Rilpivirine—Asthenia—Doxorubicin—bone cancer	4.46e-05	0.00255	CcSEcCtD
Rilpivirine—Dizziness—Epirubicin—bone cancer	4.44e-05	0.00254	CcSEcCtD
Rilpivirine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	4.44e-05	0.00174	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.44e-05	0.00174	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—NT5C3A—bone cancer	4.36e-05	0.00171	CbGpPWpGaD
Rilpivirine—Vomiting—Epirubicin—bone cancer	4.27e-05	0.00244	CcSEcCtD
Rilpivirine—Nausea—Methotrexate—bone cancer	4.26e-05	0.00244	CcSEcCtD
Rilpivirine—Diarrhoea—Doxorubicin—bone cancer	4.25e-05	0.00243	CcSEcCtD
Rilpivirine—Rash—Epirubicin—bone cancer	4.24e-05	0.00242	CcSEcCtD
Rilpivirine—Dermatitis—Epirubicin—bone cancer	4.23e-05	0.00242	CcSEcCtD
Rilpivirine—Headache—Epirubicin—bone cancer	4.21e-05	0.0024	CcSEcCtD
Rilpivirine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	4.18e-05	0.00164	CbGpPWpGaD
Rilpivirine—Dizziness—Doxorubicin—bone cancer	4.11e-05	0.00235	CcSEcCtD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.04e-05	0.00159	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—NT5C3A—bone cancer	4.04e-05	0.00159	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	4.03e-05	0.00158	CbGpPWpGaD
Rilpivirine—Nausea—Epirubicin—bone cancer	3.99e-05	0.00228	CcSEcCtD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.99e-05	0.00157	CbGpPWpGaD
Rilpivirine—Vomiting—Doxorubicin—bone cancer	3.95e-05	0.00226	CcSEcCtD
Rilpivirine—Rash—Doxorubicin—bone cancer	3.92e-05	0.00224	CcSEcCtD
Rilpivirine—Dermatitis—Doxorubicin—bone cancer	3.92e-05	0.00224	CcSEcCtD
Rilpivirine—Headache—Doxorubicin—bone cancer	3.89e-05	0.00222	CcSEcCtD
Rilpivirine—CYP2C19—Biological oxidations—GSTP1—bone cancer	3.85e-05	0.00151	CbGpPWpGaD
Rilpivirine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	3.8e-05	0.00149	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	3.78e-05	0.00148	CbGpPWpGaD
Rilpivirine—Nausea—Doxorubicin—bone cancer	3.69e-05	0.00211	CcSEcCtD
Rilpivirine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.57e-05	0.0014	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—NDUFA12—bone cancer	3.57e-05	0.0014	CbGpPWpGaD
Rilpivirine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	3.51e-05	0.00138	CbGpPWpGaD
Rilpivirine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	3.46e-05	0.00136	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.38e-05	0.00133	CbGpPWpGaD
Rilpivirine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.37e-05	0.00132	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	3.16e-05	0.00124	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.16e-05	0.00124	CbGpPWpGaD
Rilpivirine—CYP1A2—Biological oxidations—GSTP1—bone cancer	3e-05	0.00118	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—NT5C3A—bone cancer	2.96e-05	0.00116	CbGpPWpGaD
Rilpivirine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	2.96e-05	0.00116	CbGpPWpGaD
Rilpivirine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.91e-05	0.00114	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—ENO2—bone cancer	2.84e-05	0.00112	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—NDUFA12—bone cancer	2.7e-05	0.00106	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—DHFR—bone cancer	2.64e-05	0.00104	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—NDUFA12—bone cancer	2.63e-05	0.00103	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.51e-05	0.000984	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—GNA11—bone cancer	2.46e-05	0.000968	CbGpPWpGaD
Rilpivirine—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.32e-05	0.000909	CbGpPWpGaD
Rilpivirine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.28e-05	0.000897	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—NT5C3A—bone cancer	2.24e-05	0.000878	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—CYP3A4—bone cancer	2.23e-05	0.000877	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.22e-05	0.000873	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—NT5C3A—bone cancer	2.18e-05	0.000857	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—NDUFA12—bone cancer	2.1e-05	0.000826	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—GSTP1—bone cancer	1.91e-05	0.00075	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—ENO2—bone cancer	1.91e-05	0.00075	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.86e-05	0.000729	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.79e-05	0.000703	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—DHFR—bone cancer	1.77e-05	0.000696	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—ENO2—bone cancer	1.77e-05	0.000694	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—NT5C3A—bone cancer	1.74e-05	0.000684	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—GNA11—bone cancer	1.66e-05	0.00065	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—DHFR—bone cancer	1.64e-05	0.000644	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—NDUFA12—bone cancer	1.62e-05	0.000637	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.61e-05	0.000634	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—GNA11—bone cancer	1.53e-05	0.000602	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.5e-05	0.000589	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.49e-05	0.000586	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—CYP3A4—bone cancer	1.39e-05	0.000546	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.34e-05	0.000528	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—ENO2—bone cancer	1.3e-05	0.000509	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—GSTP1—bone cancer	1.28e-05	0.000504	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.27e-05	0.000498	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—DHFR—bone cancer	1.2e-05	0.000472	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—GSTP1—bone cancer	1.19e-05	0.000467	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—GNA11—bone cancer	1.12e-05	0.000441	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.07e-05	0.000418	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—CYP3A4—bone cancer	1.02e-05	0.0004	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—PTGS2—bone cancer	9.9e-06	0.000389	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—ENO2—bone cancer	9.79e-06	0.000385	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—ENO2—bone cancer	9.56e-06	0.000375	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—DHFR—bone cancer	9.09e-06	0.000357	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—DHFR—bone cancer	8.87e-06	0.000348	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—GSTP1—bone cancer	8.71e-06	0.000342	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—GNA11—bone cancer	8.49e-06	0.000333	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—GNA11—bone cancer	8.29e-06	0.000325	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—CYP3A4—bone cancer	7.7e-06	0.000302	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.66e-06	0.000301	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—ENO2—bone cancer	7.63e-06	0.0003	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—CYP3A4—bone cancer	7.51e-06	0.000295	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—DHFR—bone cancer	7.08e-06	0.000278	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—PTGS2—bone cancer	6.65e-06	0.000261	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—GNA11—bone cancer	6.62e-06	0.00026	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—GSTP1—bone cancer	6.58e-06	0.000259	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—GSTP1—bone cancer	6.43e-06	0.000252	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—PTGS2—bone cancer	6.16e-06	0.000242	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—CYP3A4—bone cancer	6e-06	0.000236	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.97e-06	0.000234	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—ENO2—bone cancer	5.89e-06	0.000231	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—DHFR—bone cancer	5.46e-06	0.000215	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—GSTP1—bone cancer	5.13e-06	0.000201	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—GNA11—bone cancer	5.11e-06	0.000201	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—PTGS2—bone cancer	4.51e-06	0.000177	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—GSTP1—bone cancer	3.96e-06	0.000155	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—PTGS2—bone cancer	3.41e-06	0.000134	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—PTGS2—bone cancer	3.33e-06	0.000131	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—PTGS2—bone cancer	2.66e-06	0.000104	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—PTGS2—bone cancer	2.05e-06	8.05e-05	CbGpPWpGaD
